Company Description
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac and preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts, including E-vita Open NEO, E-vita Open Plus, ascyrus medical dissection stent hybrid prosthesis, E-vita THORACIC 3G products, and NEXUS products.
It also offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries and aneurysmal iliac side branches; Tuva BX, a balloon-expandable peripheral stent graft to treat arterial ruptures, aneurysms, and other peripheral vascular system pathologies; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms.
In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves, and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures for mitral chordal replacement; and pyrolytic carbon coating services to medical device manufacturers.
It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons.
The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022.
Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
| Country | United States |
| Founded | 1984 |
| IPO Date | Feb 11, 1993 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 1,600 |
| CEO | James Mackin |
Contact Details
Address: 1655 Roberts Boulevard NW Kennesaw, Georgia 30144 United States | |
| Phone | (770) 419-3355 |
| Website | artivion.com |
Stock Details
| Ticker Symbol | AORT |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000784199 |
| CUSIP Number | 228903100 |
| ISIN Number | US2289031005 |
| Employer ID | 59-2417093 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| James Patrick Mackin | Chairman, President and Chief Executive Officer |
| Lance A. Berry CPA | Executive Vice President of Finance and Chief Financial Officer |
| Jean F. Holloway Esq. | Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary |
| John E. Davis | Senior Vice President and Chief Commercial Officer |
| Dr. Marshall S. Stanton M.D. | Senior Vice President of Clinical Research and Chief Medical Officer |
| Florian Tyrs | Vice President of Global Operations |
| Amy D. Horton CPA | Vice President and Chief Accounting Officer |
| Matthew A. Getz | Vice President of Human Resources and Chief Human Resources Officer |
| Dr. Robert C. Thomson Ph.D. | Vice President of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2025 | ARS | Filing |
| Apr 1, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 1, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2025 | 144 | Filing |
| Mar 11, 2025 | 144 | Filing |
| Mar 6, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 24, 2025 | 8-K | Current Report |
| Dec 23, 2024 | 8-K | Current Report |